Results 121 to 130 of about 12,196 (247)
Reduced Dopamine Transporter Uptake in Dentatorubral‐Pallidoluysian Atrophy
Movement Disorders Clinical Practice, EarlyView.
Kei Okuba +3 more
wiley +1 more source
Hypotensive Episodes Precede Cognitive Fluctuations in Parkinson's Disease Dementia
Abstract Background Cognitive fluctuations (CFs) are a disabling feature in Parkinson's disease dementia (PDD) and contribute to caregiver burden. The relationship between CFs and neurogenic orthostatic hypotension (nOH), a common autonomic complication in PDD, has not been adequately examined.
Jorge Patino +6 more
wiley +1 more source
Refractory Motor Complications: Towards a Pragmatic Definition
Movement Disorders Clinical Practice, EarlyView.
Georg Ebersbach, Tobias Warnecke
wiley +1 more source
Levodopa-Responsive Benign Tremulous Parkinsonism
Background: Benign tremulous parkinsonism (BTP) is a tremor dominant syndrome characterized by mild, levodopa-resistant parkinsonism with limited disability or progression. Case Presentation: A 56-year-old woman presented with a 2-year history of tremor.
Sayori Hanashiro +5 more
core +1 more source
Factors Associated with Early Discontinuation of Foslevodopa/Foscarbidopa in Parkinson's Disease
Movement Disorders Clinical Practice, EarlyView.
Keita Kakuda +7 more
wiley +1 more source
Abstract Background Most fall‐prediction models in Parkinson's disease (PD) rely on prior falls, limiting prevention. The Waiting Room of the Future (WROTF) platform collects standardized motor and cognitive measures during routine visits, integrated into electronic health records (EHR).
Saar Anis +5 more
wiley +1 more source
Diurnal‐Only Foslevodopa/Foscarbidopa
Movement Disorders Clinical Practice, EarlyView.
Alexandra McGuckin +3 more
wiley +1 more source
Abstract Background Non‐motor symptoms, especially autonomic dysfunction, are major contributors to disability and decreased quality of life in Parkinson's disease (PD). Despite being common and having a wide range of clinical facets, exocrine gland dysfunction is still not well recognized and managed.
Renato P. Munhoz +2 more
wiley +1 more source
As of today, levodopa remains the cornerstone of symptomatic management in Parkinson’s disease (PD). As PD progresses, the limitations of immediate-release (IR) levodopa/carbidopa, such as its short half-life and inconsistent absorption, result in ...
Fabrizio Stocchi +5 more
doaj +1 more source
FXTAS and the Spectrum of FMR1 Premutation‐Associated Phenotypes in Latin America: A Scoping Review
Abstract Background Fragile X–associated tremor/ataxia syndrome (FXTAS) is a late‐onset neurodegenerative disorder caused by FMR1 premutation expansions (55–200 CGG repeats). Although well described in populations of predominantly European ancestry, FXTAS remains poorly characterized in Latin America due to limited awareness, restricted access to ...
Amy Schmidmajer +6 more
wiley +1 more source

